What’s In Store For Merck Stock?
Merck stock jumped over 10% in a month after management dropped a confidence bomb on January 12th. They’re now saying their next-generation drugs—cardiometabolic, respiratory, and infectious disease treatments—will generate $70 billion by the mid-2030s. That’s way above earlier projections, and Wall Street loved it. Analysts bumped up price targets, investors cheered the apparent solution to the looming Keytruda patent cliff, and the rally was on.
So is this the moment to jump in?
Not so fast. Despite the excitement, we think the upside from here is limited. But before we walk through why, if you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics. Separately, see – Should You Buy Boeing Stock After Its Recent Rally?
The Valuation Picture
How expensive is Merck right now?
Actually, it looks pretty reasonable on traditional metrics:
- P/E ratio of 14.1 versus 24.2 for the S&P 500
- Price-to-free cash flow of 20.6 versus 21.6 for the index
- Price-to-sales of 4.2 versus 3.3 for the S&P (slightly higher, but not egregious)
Look at our dashboard on Merck’s Valuation Ratios for more details.
At around $110 per share, the stock trades near our fair value estimate of $109. Translation: the market has already priced in much of the good news.
What About Growth?
Here’s where things get uncomfortable.
Merck’s revenue growth has been anemic:
- 3-year average: 2.9% annually (S&P 500 did 5.6%)
- Last 12 months: 1.7% growth from $63 billion to $64 billion
- Most recent quarter: 3.7% versus last year
These aren’t the numbers of a high-growth pharma juggernaut. They’re the numbers of a company treading water.
But what about that massive pipeline promise?
That’s the $70 billion question, literally. Management says the new drugs will deliver by the mid-2030s. Great. But remember: we’re talking about offsetting the Keytruda patent cliff, not necessarily delivering net growth on top of what Keytruda currently generates (estimated $34 billion in 2026). The cliff is real, and it’s massive. For Merck to actually achieve double-digit growth despite Keytruda’s declining sales? That’s not a base case—that’s an optimistic scenario.
The Profit Story Is Strong
Okay, but Merck prints money, right?
Absolutely. This is where Merck shines:
- Operating margin of 34.9% (versus 18.8% for the S&P 500)
- Net income margin of 29.6% (versus 13.0% for the index)
- Operating cash flow margin of 26.6%
These are fortress-level margins. The business generates serious cash, no question.
Financial Health Looks Solid
Any balance sheet concerns?
None. Merck’s financial position is rock-solid:
- Debt-to-equity of just 15.4% (lower than the S&P’s 19.9%)
- Cash-to-assets ratio of 14.1% versus 7.2% for the index
- $18 billion in cash against $41 billion in debt
This company can weather storms and has plenty of firepower for deals or development.
How Does It Handle Downturns?
What happens when markets crater? Merck’s track record is mixed:
- 2022 inflation shock: Down 20%, recovered in six months
- 2020 COVID crash: Down 28%, took over two years to recover fully
- 2008 financial crisis: Down 65%, took nearly seven years to recover
The pharmaceutical giant doesn’t exactly provide a safety blanket during market chaos. It gets hit, sometimes harder than the broader market.
The Real Question: The Keytruda Cliff
Why does this patent expiration matter so much?
Because Keytruda isn’t just another drug—it’s THE drug. When that patent expires around 2028, Merck loses a cash machine. The question isn’t whether they have promising drugs in the pipeline (they do). The question is whether those drugs can replace Keytruda’s revenue AND deliver growth on top of it. See – Merck’s Keytruda Dependency: A Growth Story With An Expiration Date – for more on this.
Haven’t other pharma companies navigated this before?
Sure, with mixed results. AbbVie handled the Humira patent cliff brilliantly, and its stock has performed well. But look at Pfizer—they’re still struggling to offset the collapse in COVID vaccine sales, and the stock has suffered badly. Which path will Merck follow? We don’t know yet, and that’s the problem.
The Bottom Line
So what’s the verdict? Merck gets a “Moderate” overall rating:
- Growth: Weak
- Profitability: Very Strong
- Financial Stability: Very Strong
- Downturn Resilience: Moderate
Could we be wrong?
Of course. Investors might decide to ignore the Keytruda concerns and focus on near-term growth, which would push the stock higher. The pipeline could exceed expectations. But from where we’re sitting, with the stock already at fair value and major revenue challenges ahead, the risk-reward doesn’t favor jumping in after a 10% run.
Within pharma, we’d rather own Eli Lilly, AbbVie, or even Johnson & Johnson right now. They offer better growth prospects or more proven track records of navigating patent cliffs. Merck might prove us wrong, but until we see actual evidence that they can grow beyond 2028, best to stay on the sidelines.
Also, investing in a single stock without comprehensive analysis can be risky. Consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to produce strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks provided a responsive way to make the most of upbeat market conditions while limiting losses when markets head south, as detailed in RV Portfolio performance metrics.
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates